You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Advanced CLAD PERG system with minimal patient preparation for clinical settings (Phase II)

    SBC: JORVEC CORP.            Topic: NEI

    Abstract: Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeutic approaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroretinogram (PERG) is the only e ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Assessment of Deep Learning Classification Methods for Parkinsonism

    SBC: AUTOMATED IMAGING DIAGNOSTICS LLC            Topic: 108

    SUMMARY The growth rate in the number of people diagnosed with Parkinsonism is substantial. Estimates indicate that from 1990 to 2015 the number of Parkinsonism diagnoses doubled, with more than 6 million people currently diagnosed. By 2040, there will be between 12-14 million people diagnosed with Parkinsonism. Parkinson’s disease (PD), multiple system atrophy Parkinsonian variant (MSAp), and p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Deep-CDS: Deep Learning Semantic Data Lake for Clinical Decision Support

    SBC: INFOTECH SOFT, INC.            Topic: 300

    More than 5 million patients are admitted annually to United States ICUs with average mortality rate reported ranging from 8-19%, or about 500,000 deaths annually. Sepsis is the leading cause of in-hospital mortality, where one in three inpatient deaths are due to sepsis. Incidence of sepsis has been increasing with 1.7 million sepsis cases and 270,000 deaths per year. Early identification of dete ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT The serious unmet need to address the excessive mortality observed in patients with Acute Respiratory Distress Syndrome (ARDS) has been brought sharply into focus by the current COVID-19 pandemic. In this R-44 application, Aqualung Therapeutics will address this therapeutic gap by utilizing a novel, humanized monoclonal antibody, ALT-100 mAb, which binds/neutralizes a novel ARDS target, e ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A multi-sensor catheter for diagnosing obstructive sleep apnea

    SBC: BOLD TYPE LLC            Topic: NHLBI

    Project Summary Few medical disorders have a larger public health impact than Obstructive Sleep Apnea (OSA). OSA affects more than 20 million people in the US alone, and when untreated, it is associated with significant comorbidities and mortality. Current diagnostic tests for OSA, however, are expensive, inconvenient, and largely ineffective. Overnight in-facility sleep studies, also known as pol ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. MT-125 for the Therapeutic Treatment of Glioblastoma

    SBC: MYOSIN THERAPEUTICS INC.            Topic: 102

    PROJECT SUMMARYAn area of significant unmet need is the treatment of glioblastoma (GBM), an aggressive, fast-growing and lethal brain cancer that represents 48% of all malignant brain tumors. Untreated, GBM is fatal within three months, and due to its high rate of recurrence and invasive nature, the current standard of care, consisting of safe maximal tumor resection, radiation therapy and chemoth ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Previvors Recharge: A Resilience Program for Cancer Previvors

    SBC: Pro-Change Behavior Systems, Inc.            Topic: 102

    It is estimated that approximately 5-10% of all diagnosed cancers are caused by Hereditary Cancer Syndromes (HCS) that are associated with germline mutations (inherited genetic mutations passed directly from a parent to a child that create a genetic predisposition to certain types of cancer). Recent epidemiologic models indicate that 1 in 279 people may be carriers of one of the most common HCS, a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. High-throughput functional analysis and clinical relevance of all possible variants of a gene

    SBC: HELIGENICS, INC.            Topic: NHGRI

    Modern pharmaceuticals have greatly improved the quality of life for many patients suffering a variety of illnesses. Unfortunately, among the 17 most commonly prescribed drugs, only 6 are highly effective for most patients, 5 have a modest effect, and 6 show little clinical effect. Worse still, unwanted illness and death from treatment of patients with the incorrect drug or dosage causes over 275, ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A mobile health framework for left ventricular end diastolic pressure diagnostics and monitoring.

    SBC: AVENTUSOFT L.L.C.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT This SBIR Fast-Track project will develop a novel mobile health framework for left ventricular end diastolic pressure diagnostics and monitoring, using an innovative, non-invasive cardiac biosensor. Heart disease is the leading cause of death for men and women accounting for more than one-third (33.6%) of all U.S. deaths. The total costs associated with cardiovascular dise ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Process development for manufacturing eCD4-Ig

    SBC: EMMUNE INC            Topic: NIAID

    ABSTRACTeCD4-Ig is an antibody-like therapeutic for HIV that was constructed by fusing CD4 domains 1 and 2, and an HIV coreceptor-mimetic sulfopeptide, to the N- and C-termini of the constant Fc region of an antibody. eCD4-Ig will join an emerging class of long-acting therapeutics for treating and preventing HIV infection. As a consequence of being built from parts of HIV’s receptors, eCD4-Ig ne ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government